ads

Cell Therapeutics Jumps 12%; Ladenburg Thalman Initiates With Buy Rating

Cell Therapeutics Jumps 12%; Ladenburg Thalman Initiates With Buy Rating

Cell Therapeutics (CTIC) shares were higher 12% as Ladenburg Thalmann initiated coverage of the biopharmaceutical company's stock with a buy rating and a price target at $6.00. CTIC is trading in the upper half of the 52-week range between $0.97 and $4.25.

Cell Therapeutics Jumps 12%; Ladenburg Thalman Initiates With Buy Rating